Dr. Abrar Qureshi highlights new and upcoming therapies across complex skin conditions, including subcutaneous anifrolumab and litifilimab for cutaneous lupus, alongside brepocitinib, the first approved drug for dermatomyositis. He outlines progress in scleroderma treatments targeting interleukin-33 and details the use of spesolimab in both intravenous and subcutaneous forms for generalized pustular psoriasis. Additionally, he touches on testing protocols and targeted therapies like avapritinib for mast cell disease. Finally, he points to promising new clinical data for hidradenitis suppurativa involving oral JAK inhibitors, such as povorcitinib and upadacitinib.